We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Dr Eric Winer (President, American Society of Clinical Oncology [ASCO]) discusses the global following that the society has and the current collaborations in discussion with the European Cancer Organisation. He also shares his focus on combating physician burnout and how the society are working on ensuring that the cancer workforce are well supported throughout their career. […]
Dr Eric Winer (President, American Society of Clinical Oncology [ASCO]) discusses what’s in store for the society for 2023, with particular attention on the importance of patient-physician partnerships. He explains that establishing a strong connection can help physicians rediscover the joy in their work, therefore helping to reduce the risk of burnout, which unfortunately so many […]
Dr Eric Winer (President, American Society of Clinical Oncology [ASCO]) shares his highlights from the recently-concluded European Cancer Summit 2022, held in Brussels. He focuses particularly on the opening session ‘Action on Cancer Inequalities: Our Shared Roadmap’, which aims to achieve a 70% survival rate, on average, for all cancer patients in Europe by 2035. […]
Primary cancer prevention can help individuals choose healthy behaviors that could substantially lower their cancer risk, but how can these important messages be delivered to the right people and in the most effective way? Nurses could play an important part. With a solid education in health promotion and the opportunity to meet and build numerous […]
According to the World Health Organization (WHO) between 30% to 50% of cancers could be preventable1. Launched in September 2022, the “Cancer Prevention Across Europe” campaign (PrEvCan) aims to help address this statistic and reduce the burden of cancer. Initiated, and led, by the European Oncology Nurses Society (EONS) we were delighted to speak with […]
Patients with locally advanced bladder cancer have a poor prognosis despite surgical therapy. Prof. Sebastian Schmid (Technical University of Munich, Munich, Germany) joins touchONCOLOGY to discuss the unmet needs in the treatment of locally advanced bladder cancer, and also discusses the feasibility, safety and efficacy of neoadjuvant radio-immunotherapy following radical cystectomy in patients with locally […]
First-line immunotherapy is a standard treatment for patients with advanced non-small cell lung cancer. Prof. Gerard Zalcman (Bichat Hospital, Assistance Publique-Hôpitaux de Paris; Institute of Cancer AP-HP Nord, Paris, France) joins touchONCOLOGY to discuss the IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab, aiming to assess if 6-months nivolumab/ipilimumab duration was equivalent to continuation until progression […]
The Phase III SOLO1/GOG-3004 trial (NCT01844986), investigated maintenance olaparib, which provided sustained benefit beyond the end of treatment in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Prof. Paul DiSilvestro (Brown University, Providence, RI, USA) joins touchONCOLOGY to discuss the efficacy and safety of maintenance olaparib, and overall survival findings at 7 years. […]
The ABC-06 clinical trial established active-symptom control + oxaliplatin/5-FU chemotherapy (FOLFOX) as the standard of care treatment after Cisplatin and Gemcitabine for advanced biliary cancers. Dr Angela Lamarca (Fundación Jiménez Diaz University Hospital, Madrid, Spain) joins touchONCOLOGY to discuss the efficacy and safety of second-line active- symptom-control with FOLFOX, and the quality of life and […]
Get the latest clinical insights from touchONCOLOGY